Adaptive Biotechnologies Corp (ADPT) received a notice that former officer Harlan Robins intends to sell shares of its common stock under Rule 144. The planned sale covers 261,044 shares, with an indicated aggregate market value of $6,411,240.64. Shares outstanding were listed as 159,595,842 as of 08/18/2026; this is a baseline figure, not the amount being sold.
The shares to be sold were originally acquired on 02/07/2019 as stock option compensation, with the planned transaction described as a cashless exercise / same-day sale through Goldman Sachs & Co. LLC. The notice also lists multiple prior common stock sales by Harlan Robins in the preceding three months, including blocks of 250,000 shares on 07/02/2026 and 207,600 shares plus 284,800 shares on 07/21/2026.
For ticker ADPT, Harlan Robins filed a notice of intent to sell 300,992 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $7,455,571.84, in transactions expected on or after 08/17/2026.
The shares to be sold include stock acquired as performance awards on 03/10/2026 and through stock options granted 02/07/2019, including a cashless exercise/same‑day sale component. The filing also lists multiple prior common stock sales by Robins during June and July 2026.
ADPT reported a planned sale of restricted securities under Rule 144. The planned transaction covers 321,324 shares of common stock to be sold through Goldman Sachs & Co. LLC. The shares have an aggregate market value of $7,959,195.48, based on the filer’s stated valuation.
The shares relate to stock options originally acquired as compensation on February 7, 2018, with the disposition described as a compensation – cashless exercise / same-day sale. At the time of this notice, 159,595,842 shares of the issuer’s common stock were outstanding, providing context for the size of the proposed sale. The proposed sale date is August 17, 2026 on the NASD market.
Adaptive Biotechnologies Corp. (ADPT) reports a planned sale of common stock under a Form 144. The disclosure lists 124,690 common shares to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, alongside a dollar figure of $3,136,046.03 and a share figure of 159,595,842 as of 08/17/2026. The breakdown of securities covers stock option exercise shares, restricted stock grants from several grant dates, and previously exercised shares, all scheduled in connection with a planned sale date of 08/17/2026 on NASDAQ.
Adaptive Biotechnologies Corp executive Susan Bobulsky, Chief Commercial Officer, MRD, reported selling 3,000 shares of common stock on August 10, 2026 at $25.00 per share in an open market or private transaction. Following this sale, she directly holds 396,989 shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 16, 2025.
A holder of ADPT common stock filed a Form 144 indicating an intention to sell 3,000 shares through Morgan Stanley Smith Barney, with an aggregate market value of $74,790.00 as of August 10, 2026 on NASDAQ. These shares relate to Restricted Stock Units acquired from the issuer on March 4, 2023. The filing also lists recent Rule 10b5-1 plan sales for Susan Bobulsky over the past three months, including transactions of 11,000, 5,000, and 1,299 common shares on various dates in June and July 2026.
Adaptive Biotechnologies Corporation reported Q2 2026 revenue of $71.6 million, up from $58.9 million a year earlier, driven mainly by MRD service revenue. Immune Medicine revenue was smaller, and net loss attributable to the company widened to $39.8 million, or $0.25 per share, including a $23.7 million loss on extinguishing a revenue interest liability.
Cash, cash equivalents and marketable securities increased to $371.7 million at June 30, 2026. The company issued $345.0 million of 0% convertible senior notes due 2031, used $156.9 million of the proceeds to repurchase all Revenue Interests, spent $25.0 million to repurchase 1,451,800 shares, and entered capped call transactions intended to limit dilution from the notes.
MRD generated positive Adjusted EBITDA, while Immune Medicine remained loss-making. Management plans to separate the MRD and Immune Medicine businesses by identifying a preferred separation path by year-end 2026 and will wind down the Adaptive Immunosequencing research-use-only service to focus Immune Medicine on its TCR-antigen dataset and target discovery platform.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,299 shares of Common Stock on July 30, 2026 at $24.00 per share in an open-market or private transaction. Following this sale, she directly holds 399,989 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was executed under a pre-arranged trading framework.
Adaptive Biotechnologies Corporation filed to sell common stock held by insider Susan Bobulsky through a brokerage account at Morgan Stanley Smith Barney LLC, with sales conducted under a Rule 10b5-1 trading plan. Recent reported transactions include multiple open-market sales of common shares on NASDAQ between June and July 2026.
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, up 22% from a year earlier, led by its Minimal Residual Disease (MRD) segment. MRD revenue reached $66.2 million, a 33% increase, while Immune Medicine revenue was $5.4 million, a 40% decrease, though up 8% excluding prior Genentech-related revenue. clonoSEQ test volume rose 43% to 36,111 tests. Adjusted EBITDA loss narrowed sharply to $0.7 million, compared with a $7.2 million loss in the prior-year quarter.
Net loss was $39.9 million, including a $23.7 million loss on extinguishment of a revenue interest liability tied to settling the OrbiMed Purchase Agreement; excluding this, net loss was $16.2 million. The company completed a $345 million zero-coupon convertible senior notes offering, repaid the OrbiMed obligation, and ended June 30, 2026 with $371.7 million in cash, cash equivalents and marketable securities. Full-year 2026 MRD revenue guidance was raised to $268–$278 million, and total operating expense guidance was set at $350–$355 million. Co-founder and Chief Scientific Officer Harlan Robins will transition to a strategic consultant role focused on MRD R&D and the planned separation of the Immune Medicine business; the company states there are no disagreements or performance issues related to his decision.